PATENT CLAIM ANALYSIS

Application Number: 16444032
Application Type: Utility
Filing Date: 2019-06
Publication Date: 2019-10
Patent Classification: ["514", "210180"]

Abstract:
The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein X, Y, Z, R 1 , R 2 , R 4  and R 7  are defined herein.

Claim (Index 53):
The process of  claim 35 , wherein the compound of Formula (VI) is selected from:\n cyclobutyl (3S)-4-acetyl-7-[1-(1,1-dioxo-1\u03bb 6 -thian-4-yl)-1H-pyrazol-4-yl]-3-methyl-1,2,3,4-tetrahydroquinoxaline-1-carboxylate; cyclobutyl (3S)-4-acetyl-7-{1-[(3R)-1,1-dioxo-1\u03bb 6 -thian-3-yl]-1H-pyrazol-4-yl}-3-methyl-1,2,3,4-tetrahydroquinoxaline-1-carboxylate; and cyclobutyl (3S)-4-acetyl-7-{1-[(3S)-1,1-dioxo-1\u03bb 6 -thian-3-yl]-1H-pyrazol-4-yl}-3-methyl-1,2,3,4-tetrahydroquinoxaline-1-carboxylate.

Metadata:
- Claim Count in Document: 92.0
- Percentile: 100.0
- Lexical Diversity: 1.39535
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16029166', '14546896', '16225484', '14546775', '15247429']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8272451941182468
- 35 USC 102 Novelty (BERT): 0.6673702612039141
- Combined Prediction Score: 0.8112577008268136
- Mean Citation Score: 465.056012
- Max Citation Score: 586.20514
- Similarity Product: 511.9316652977968

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test